|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
3
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
4
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21(Suppl 7): vii89–92.
2010.
|
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwatsuki M, Mimori K, Yokobori T, et al:
Epithelial-mesenchymal transition in cancer development and its
clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rhim AD, Mirek ET, Aiello NM, et al: EMT
and dissemination precede pancreatic tumor formation. Cell.
148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cano CE, Motoo Y and Iovanna JL:
Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.
ScientificWorldJournal. 10:1947–1957. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krantz SB, Shields MA, Dangi-Garimella S,
Munshi HG and Bentrem DJ: Contribution of epithelial-to-mesenchymal
transition and cancer stem cells to pancreatic cancer progression.
J Surg Res. 173:105–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim T, Veronese A, Pichiorri F, et al: p53
regulates epithelial-mesenchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tellez CS, Juri DE, Do K, et al: EMT and
stem cell-like properties associated with miR-205 and miR-200
epigenetic silencing are early manifestations during
carcinogen-induced transformation of human lung epithelial cells.
Cancer Res. 71:3087–3097. 2011. View Article : Google Scholar
|
|
14
|
Li Y, Van den Boom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jantscheff P, Terracciano L, Lowy A, et
al: Expression of CEACAM6 in resectable colorectal cancer: a factor
of independent prognostic significance. J Clin Oncol. 21:3638–3646.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maraqa L, Cummings M, Peter MB, et al:
Carcinoembryonic antigen cell adhesion molecule 6 predicts breast
cancer recurrence following adjuvant tamoxifen. Clin Cancer Res.
14:405–411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poola I, Shokrani B, Bhatnagar R, DeWitty
RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell
adhesion molecule 6 oncoprotein in atypical ductal hyperplastic
tissues is associated with the development of invasive breast
cancer. Clin Cancer Res. 12:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singer BB, Scheffrahn I, Kammerer R,
Suttorp N, Ergun S and Slevogt H: Deregulation of the CEACAM
expression pattern causes undifferentiated cell growth in human
lung adenocarcinoma cells. PLoS One. 5:e87472010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ieta K, Tanaka F, Utsunomiya T, Kuwano H
and Mori M: CEACAM6 gene expression in intrahepatic
cholangiocarcinoma. Br J Cancer. 95:532–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Strickland LA, Ross J, Williams S, et al:
Preclinical evaluation of carcinoembryonic cell adhesion molecule
(CEACAM) 6 as potential therapy target for pancreatic
adenocarcinoma. J Pathol. 218:380–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and
in vivo metastatic ability of pancreatic adenocarcinoma
cells. Oncogene. 23:465–473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iacobuzio-Donahue CA, Maitra A, Olsen M,
et al: Exploration of global gene expression patterns in pancreatic
adenocarcinoma using cDNA microarrays. Am J Pathol. 162:1151–1162.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duxbury MS, Ito H, Benoit E, Waseem T,
Ashley SW and Whang EE: A novel role for carcinoembryonic
antigen-related cell adhesion molecule 6 as a determinant of
gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Cancer Res. 64:3987–3993. 2004. View Article : Google Scholar
|
|
24
|
Fu X, Tao L, Li M, Fisher WE and Zhang X:
Effective treatment of pancreatic cancer xenografts with a
conditionally replicating virus derived from type 2 herpes simplex
virus. Clin Cancer Res. 12:3152–3157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duxbury MS, Matros E, Clancy T, et al:
CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN
lesions. Ann Surg. 241:491–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duxbury MS, Ito H, Benoit E, Zinner MJ,
Ashley SW and Whang EE: Overexpression of CEACAM6 promotes
insulin-like growth factor I-induced pancreatic adenocarcinoma
cellular invasiveness. Oncogene. 23:5834–5842. 2004. View Article : Google Scholar
|
|
27
|
Duxbury MS, Ito H, Benoit E, Ashley SW and
Whang EE: CEACAM6 is a determinant of pancreatic adenocarcinoma
cellular invasiveness. Br J Cancer. 91:1384–1390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lewis-Wambi JS, Cunliffe HE, Kim HR,
Willis AL and Jordan VC: Overexpression of CEACAM6 promotes
migration and invasion of oestrogen-deprived breast cancer cells.
Eur J Cancer. 44:1770–1779. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
the importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eastham AM, Spencer H, Soncin F, Ritson S,
Merry CL, Stern PL and Ward CM: Epithelial-mesenchymal transition
events during human embryonic stem cell differentiation. Cancer
Res. 67:11254–11262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leshem O, Madar S, Kogan-Sakin I, et al:
TMPRSS2/ERG promotes epithelial to mesenchymal transition through
the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One.
6:e216502011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cummins JM, He Y, Leary RJ, et al: The
colorectal microRNAome. Proc Natl Acad Sci USA. 103:3687–3692.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Braconi C, Kogure T, Valeri N, et al:
microRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene. 30:4750–4756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorigenicity and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.PubMed/NCBI
|
